PharmaPoint: Major Depressive Disorder – Global Drug Forecast and Market Assessment to 2025

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$10995
Buy Report View Sample

Published: October 01, 2016 Report Code: GDHC126PIDR-ST

Select Item

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized by single or recurrent major depressive episodes (MDEs), where patients can typically experience periods of depressed mood, loss of energy, abnormal cognition, anxiety and suicidal ideation. Similar to other neuropsychiatric disorders, MDD has a multifaceted and varied etiology, and remains poorly understood. The MDD market is crowded and competitive, with more than 30 products available for the treatment of patients, the majority of which are now available as inexpensive generics. The MDD market is therefore in a dynamic phase where patent expiries for historically top-selling products such as Eli Lilly's Cymbalta and Otsuka/BMS' Abilify have occurred, and recent launches of Lundbeck/Takeda's Trintellix and Otsuka/Lundbeck's Rexulti will be a significant driver of growth in the 7MM. Growth in the MDD market is also expected to be driven by the potential introduction of six promising late-stage pipeline products into the market during the forecast period, all of which are directed towards treatment-resistant patients, a significant unmet need.

Scope

Overview of MDD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

Annualized MDD market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.

Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the MDD therapeutics market.

Pipeline analysis: focus on eight late-stage pipeline MDD drugs, discussing emerging trends as well as an overview of earlier phase drugs.

Analysis of the current and future market competition in the global MDD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

The MDD market is widely genericized. In light of this, what are the current clinical and environmental unmet needs? Will there be opportunities in this market for drug developers throughout the forecast period?

There are five substantial unmet needs that exist in the MDD market. Will pipeline drugs fulfil any of the unmet needs for MDD? Which unmet needs will continue to provide opportunity for drug developers during the forecast period?

Six late-stage pipeline products are expected to launch during the forecast period to 2025. What impact will these drugs have on the market? How will they affect the treatment algorithm for MDD?

AbbVie
Abbott Laboratories
Alkermes
Allergan
Asahi Kasei
Astellas
AstraZeneca
Avanir Pharmaceuticals
Axsome Therapeutics
Bristol-Myers Squibb
e-Therapeutics
Eli Lilly
GlaxoSmithKline
Gedeon Richter
Janssen
Lundbeck
Meiji Seika
Merck & Co.
Methylation Sciences
Minerva Neurosciences
Mitsubishi Tanabe Pharma
Mochida
Moksha8
Neuralstem Pharmaceuticals
Novartis
Otsuka
Pfizer
Pierre Fabre
Royalty Pharma
Sandoz
Shionogi
Takeda
Teva Pharmaceutical
Yoshitomi Yakuhin Corporation

Table of Contents

1Table of Contents

1.1List of Tables

1.2List of Figures

2Introduction

2.1Related Reports

2.2Upcoming Related Reports

3Disease Overview

3.1Etiology and Pathophysiology

3.1.1Etiology

3.1.2Pathophysiology

3.2Classification

3.3Symptoms and Subtypes of Major Depressive Disorder

3.4Prognosis

3.5Quality of Life

4Epidemiology

4.1Disease Background

4.2Risk Factors and Comorbidities

4.3Global Trends

4.4Forecast Methodology

4.4.1Sources Used Tables

4.4.2Forecast Assumptions and Methods

4.4.3Sources Not Used

4.5Epidemiological Forecast for MDD (2015–2025)

4.5.112-Month Total Prevalent Cases of MDD

4.5.2Age-Specific 12-Month Total Prevalent Cases of MDD

4.5.3Sex-Specific 12-Month Total Prevalent Cases of MDD

4.5.4Age-Standardized 12-Month Total Prevalence of MDD

4.5.512-Month Total Prevalent Cases of MDD by Severity

4.6Discussion

4.6.1Epidemiological Forecast Insight

4.6.2Limitations of the Analysis

4.6.3Strengths of the Analysis

5Disease Management

5.1Diagnosis and Treatment Overview

5.1.1Diagnosis

5.1.2Treatment Guidelines

5.1.3Clinical Practice

5.2US

5.35EU

5.4Japan

6Competitive Assessment

6.1Overview

6.2Selective Serotonin Reuptake Inhibitors

6.2.1Lexapro (Escitalopram)

6.2.2Viibryd (Vilazodone)

6.2.3Other Selective Serotonin Reuptake Inhibitors

6.3Serotonin-Norepinephrine Reuptake Inhibitors

6.3.1Cymbalta (Duloxetine)

6.3.2Effexor (Venlafaxine)

6.3.3Fetzima (Levomilnacipran)

6.3.4Savella (Milnacipran)

6.3.5Pristiq (Desvenlafaxine)

6.4Multimodal Antidepressants

6.4.1Trintellix (Vortioxetine)

6.5Other Antidepressants

6.5.1Bupropion

6.5.2Symbyax (Olanzapine/Fluoxetine)

6.5.3Mirtazapine

6.5.4Monoamine Oxidase Inhibitors

6.5.5Tricyclic Antidepressants

6.6Antipsychotics

6.6.1Abilify (Aripiprazole)

6.6.2Seroquel XR (Quetiapine XR)

6.6.3Rexulti (Brexpiprazole)

6.7Other Therapeutic Classes

7Unmet Need and Opportunity

7.1Overview

7.2New Therapies with Better Efficacy

7.2.1Unmet Need

7.2.2Gap Analysis

7.2.3Opportunity

7.3Improved Safety Profiles

7.3.1Unmet Need

7.3.2Gap Analysis

7.3.3Opportunity

7.4Rapid Onset of Action

7.4.1Unmet Need

7.4.2Gap Analysis

7.4.3Opportunity

7.5Personalized Treatment Approach

7.5.1Unmet Need

7.5.2Gap Analysis

7.5.3Opportunity

7.6Manage Patient Outcome Expectations

7.6.1Unmet Need

7.6.2Gap Analysis

7.6.3Opportunity

8Pipeline Assessment

8.1Overview

8.2Clinical Trial Mapping

8.2.1Clinical Trials by Class of Therapy

8.3Promising Drugs in Clinical Development

8.3.1ALKS-5461

8.3.2Vraylar (Cariprazine)

8.3.3ASC-01

8.3.4AXS-05

8.3.5Esketamine

8.3.6Rapastinel (GLYX-13)

8.3.7Strada (MSI-195)

8.3.8Viotra (Tramadol)

8.4Promising Drugs in Early-Stage Development

8.4.1CGP3466B

8.4.2NSI-189

8.5Other Drugs in Development

9Current and Future Players

9.1Overview

9.2Trends in Corporate Strategy

9.3Company Profiles

9.3.1Allergan

9.3.2e-Therapeutics

9.3.3Alkermes

9.3.4Pfizer

9.3.5Otsuka

9.3.6Janssen

9.3.7Eli Lilly

9.3.8Lundbeck

9.3.9Takeda

9.3.10Axsome Therapeutics

10Market Outlook

10.1Global Markets

10.1.1Forecast

10.1.2Drivers and Barriers – Global Issues

10.2US

10.2.1Forecast

10.2.2Key Events

10.2.3Drivers and Barriers

10.35EU

10.3.1Forecast

10.3.2Key Events

10.3.3Drivers and Barriers

10.4Japan

10.4.1Forecast

10.4.2Key Events

10.4.3Drivers and Barriers

11Appendix

11.1Bibliography

11.2Abbreviations

11.3Methodology

11.4Forecasting Methodology

11.4.1Diagnosed MDD Patients

11.4.2Percent Drug-Treated Patients

11.4.3Percent Treatment-Resistant Patients

11.4.4Drugs Included in Each Therapeutic Class

11.4.5Key Launch Dates and Patent Expiries

11.4.6General Pricing Assumptions

11.4.7Individual Drug Assumptions

11.4.8Generic Erosion

11.4.9Pricing of Pipeline Agents

11.5Primary Research – KOLs Interviewed for this Report

11.6Primary Research – High-Prescriber Survey

11.7About the Authors

11.7.1Analysts

11.7.2Therapy Area Director

11.7.3Epidemiologist

11.7.4Global Director of Therapy Analysis and Epidemiology

11.8About GlobalData

11.9Disclaimer

Table

Table 1: Classification and Criteria of MDD (DSM-IV) and MDE (ICD-10)

Table 2: Subtypes of Major Depressive Disorder

Table 3: DSM-IV Diagnostic Criteria for MDD

Table 4: Risk Factors and Comorbidities for MDD

Table 5: Prevalence of the Most Frequent Psychiatric Comorbidities in Individuals With and Without MDD, Ages 18–64 Years

Table 6: 7MM, Total Prevalence (%) of MDD According to the DSM-IV Criteria, =18 Years

Table 7: 7MM, Total Prevalence (%) of MDD According to the DSM-III Criteria

Table 8: 7MM, Sources Used to Forecast the 12-Month Total Prevalence of MDD

Table 9: Sources Used to Forecast the 12-Month Total Prevalent Cases of MDD by Severity

Table 10: 7MM, Sources Not Used in Epidemiological Forecast for the 12-Month Total Prevalent Cases of MDD

Table 11: 7MM, 12-Month Total Prevalent Cases of MDD, Ages =18 Years, Both Sexes, N, Selected Years 2015–2025

Table 12: 7MM, 12-Month Total Prevalent Cases of MDD, by Age, Both Sexes, N (Row %), 2015

Table 13: 7MM, 12-Month Total Prevalent Cases of MDD, by Sex, Ages =18 Years, N (Row %), 2015

Table 14: Severity of Depressive Episodes According to ICD-10 and DSM-IV Diagnostic Criteria

Table 15: Treatment Guidelines for Major Depressive Disorder

Table 16: Most-Prescribed Drugs for MDD by Class in the 7MM, 2015

Table 17: Country Profile – US

Table 18: Country Profile – 5EU

Table 19: Country Profile – Japan

Table 20: Leading Treatments for MDD, 2016

Table 21: Product Profile – Lexapro

Table 22: Lexapro/Cipralex SWOT Analysis, 2016

Table 23: Product Profile – Viibryd

Table 24: Summary of Efficacy Results for the Primary Endpoint in Viibryd Clinical Trials

Table 25: Viibryd SWOT Analysis, 2016

Table 26: Summary of SSRIs, 2016

Table 27: SSRIs SWOT Analysis, 2016

Table 28: Product Profile – Cymbalta

Table 29: Cymbalta SWOT Analysis, 2016

Table 30: Product Profile – Effexor

Table 31: Effexor SWOT Analysis, 2016

Table 32: Product Profile – Fetzima

Table 33: Fetzima SWOT Analysis, 2016

Table 34: Product Profile – Savella

Table 35: Savella SWOT Analysis, 2016

Table 36: Product Profile – Pristiq

Table 37: Pristiq SWOT Analysis, 2016

Table 38: Product Profile – Trintellix

Table 39: Trintellix SWOT Analysis, 2016

Table 40: Product Profile – Bupropion

Table 41: Bupropion SWOT Analysis, 2016

Table 42: Product Profile – Symbyax

Table 43: Symbyax SWOT Analysis, 2016

Table 44: Product Profile – Mirtazapine

Table 45: Mirtazapine SWOT Analysis, 2016

Table 46: MAOIs SWOT Analysis, 2016

Table 47: TCAs SWOT Analysis, 2016

Table 48: Product Profile – Abilify

Table 49: Abilify SWOT Analysis, 2016

Table 50: Product Profile – Seroquel XR

Table 51: Seroquel XR SWOT Analysis, 2016

Table 52: Product Profile – Rexulti

Table 53: Rexulti SWOT Analysis, 2016

Table 54: Summary of Minor Therapeutic Classes in MDD, 2016

Table 55: Unmet Needs and Opportunities in MDD

Table 56: Promising Drugs in Clinical Development for MDD, 2016

Table 57: Comparison of Drugs in Development for MDD, 2016

Table 58: Product Profile – ALKS-5461

Table 59: SWOT Analysis – ALKS-5461, 2016

Table 60: Product Profile – Vraylar

Table 61: SWOT Analysis – Vraylar, 2016

Table 62: Product Profile – ASC-01

Table 63: SWOT Analysis – ASC-01, 2016

Table 64: Product Profile – AXS-05

Table 65: SWOT Analysis – AXS-05, 2016

Table 66: Product Profile – Esketamine

Table 67: SWOT Analysis – Esketamine, 2016

Table 68: Product Profile – Rapastinel

Table 69: SWOT Analysis – Rapastinel, 2016

Table 70: Product Profile – Strada

Table 71: SWOT Analysis – Strada, 2016

Table 72: Product Profile – Viotra

Table 73: SWOT Analysis – Viotra, 2015

Table 74: Drugs in Development, 2016

Table 75: Key Companies in the MDD Market in the 7MM

Table 76: Allergan’s MDD Portfolio Assessment, 2016

Table 77: Allergan SWOT Analysis in MDD, 2015–2025

Table 78: e-Therapeutics’ MDD Portfolio Assessment, 2016

Table 79: e-Therapeutics SWOT Analysis in MDD, 2015–2025

Table 80: Alkermes’ MDD Portfolio Assessment, 2016

Table 81: Alkermes SWOT Analysis in MDD, 2015–2025

Table 82: Pfizer’s MDD Portfolio Assessment, 2016

Table 83: Pfizer SWOT Analysis in MDD, 2015–2025

Table 84: Otsuka’s MDD Portfolio Assessment, 2016

Table 85: Otsuka SWOT Analysis in MDD, 2015–2025

Table 86: Janssen’s MDD Portfolio Assessment, 2016

Table 87: Janssen SWOT Analysis in MDD, 2015–2025

Table 88: Eli Lilly’s MDD Portfolio Assessment, 2016

Table 89: Eli Lilly SWOT Analysis in MDD, 2015–2025

Table 90: Lundbeck’s MDD Portfolio Assessment, 2016

Table 91: Lundbeck SWOT Analysis in MDD, 2015–2025

Table 92: Takeda’s MDD Portfolio Assessment, 2016

Table 93: Takeda SWOT Analysis in MDD, 2015–2025

Table 94: Axsome Therapeutics’ MDD Portfolio Assessment, 2016

Table 95: Axsome Therapeutics SWOT Analysis in MDD, 2015–2025

Table 96: MDD Market – Drivers and Barriers, 2015–2025

Table 97: Key Events Impacting Sales for MDD Therapies in the US, 2015–2025

Table 98: MDD Market – Drivers and Barriers in the US, 2015–2025

Table 99: Key Events Impacting Sales for MDD Therapies in the 5EU, 2015–2025

Table 100: MDD Market – Drivers and Barriers in the 5EU, 2015–2025

Table 101: National Healthcare Authorities and Governmental Drug Pricing Authorities in the 5EU

Table 102: Key Events Impacting Sales for MDD Therapies in Japan, 2015–2025

Table 103: MDD Market – Drivers and Barriers in Japan, 2015–2025

Table 104: Key Launch Dates

Table 105: Key Patent Expiries

Table 106: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country

Figures

Figure 1: Overview of Targets of Antidepressant Action on Noradrenergic and Serotonergic Neurons

Figure 2: 7MM, 12-Month Total Prevalent Cases of MDD, Ages =18 Years, Both Sexes, N, 2015–2025

Figure 3: 7MM, 12-Month Total Prevalent Cases of MDD, by Age, Both Sexes, N, 2015

Figure 4: 7MM, 12-Month Total Prevalent Cases of MDD, by Sex, Ages =18 Years, N, 2015

Figure 5: 7MM, Age-Standardized 12-Month Total Prevalence (%) of MDD, by Sex, Ages =18 Years, 2015

Figure 6: 7MM, 12-Month Total Prevalent Cases of MDD by Severity, Both Sexes, Ages =18 Years, 2015

Figure 7: Disease Management Model for Major Depressive Disorder

Figure 8: Major Depressive Disorder Treatment Algorithm

Figure 9: MDD Therapeutics – Phase II and III Clinical Trials in the 7MM, 2016

Figure 10: MDD Phase II/Phase III Pipeline, 2016

Figure 11: Competitive Assessment of Late-Stage Pipeline Agents in MDD, 2015–2025

Figure 12: Clinical and Commercial Positioning of ALKS-5461

Figure 13: Clinical and Commercial Positioning of Vraylar

Figure 14: Clinical and Commercial Positioning of ASC-01

Figure 15: Clinical and Commercial Positioning of AXS-05

Figure 16: Clinical and Commercial Positioning of Esketamine

Figure 17: Clinical and Commercial Positioning of Rapastinel

Figure 18: Clinical and Commercial Positioning of Strada

Figure 19: Clinical and Commercial Positioning of Viotra

Figure 20: Company Portfolio Gap Analysis in MDD, 2015–2025

Figure 21: Global Sales by Region for MDD Therapies, 2015 and 2025

Figure 22: Global Sales by Region for MDD Therapies, 2015–2025

Figure 23: Global Sales by Drug Class for MDD Therapies, 2015 and 2025

Figure 24: Global Sales by Drug Class for MDD Therapies, 2015–2025

Figure 25: US Sales by Drug Class for MDD Therapies, 2015 and 2025

Figure 26: US Sales by Drug Class for MDD Therapies, 2015–2025

Figure 27: 5EU Sales by Drug Class for MDD Therapies, 2015 and 2025

Figure 28: 5EU Sales by Drug Class for MDD Therapies, 2015–2025

Figure 29: 5EU Sales by Region for MDD Therapies, 2015 and 2025

Figure 30: Japan Sales by Drug Class for MDD Therapies, 2015 and 2025

Figure 31: Japan Sales by Drug Class for MDD Therapies, 2015–2025

Frequently asked questions

PharmaPoint: Major Depressive Disorder – Global Drug Forecast and Market Assessment to 2025 standard reports
Currency USD
$10,995

Can be used by individual purchaser only

Most Popular
$21,990

Can be shared by unlimited users within one corporate location e.g. a regional office

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

PharmaPoint: Major Depressive Disorder – Global Drug Forecast and Market Assessment to 2025 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Central Nervous System reports
Pharmaceuticals
New
New Drug Approvals and Their Contract Manufacture - 2024 Edition
$4,995 | April 2024
Pharmaceuticals
New
Methicillin-Resistant Staphylococcus aureus (MRSA) Epidemiology Analysis and Forecast to 2033
$3,995 | April 2024
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at PharmaPoint: Major Depressive Disorder – Global Drug Forecast and Market Assessment to 2025 in real time.

  • Access a live PharmaPoint: Major Depressive Disorder – Global Drug Forecast and Market Assessment to 2025 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more